Pharmacoepidemiological characteristics of antibacterial drug prescriptions used in patients with exacerbation of chronic pyelonephritis in real-life practice in Kursk and Chisinau

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Background. Urinary tract infections (UTIs) are among the most common diseases. One of the promising ways to optimize antibacterial therapy for UTIs is to conduct pharmacoepidemiological studies.

Objective. Evaluation of the structure of medical prescriptions for antibacterial drugs used in patients with exacerbation of chronic pyelonephritis (PN) in real-life practice in Kursk (Russian Federation) and Chisinau (Republic of Moldova).

Materials and methods. The research method was a survey of doctors of various specialties in outpatient medical organizations in Kursk – group 1 and Chisinau – group 2. From October 2019 to January 2020, 140 respondents were surveyed; the study design corresponded to a cross-sectional descriptive one.

Results. The majority of respondents gave leading positions to fluoroquinolones, cephalosporins, and drugs from other groups. For respondents of the 1st group, the priority (in descending order) were fluoroquinolones, cephalosporins, and drugs from other groups (41.0%, 24.4, and 12.2%, respectively). For doctors of the 2nd group, the leaders were drugs from other groups (26.1%), followed by fluoroquinolones and cephalosporins (25.0 and 20.5%, respectively).

Conclusion. In general, the compliance of medical prescriptions with current clinical guidelines was established. Along with this, it is necessary to note the episodic use of non-recommended groups of antibacterial drugs or their individual representatives.

Толық мәтін

Рұқсат жабық

Авторлар туралы

S. Povetkin

Kursk State Medical University

Email: clinfarm@kursknet.ru
ORCID iD: 0000-0002-1302-9326

Dr. Sci. (Med.), Professor, Head of the Department of Clinical Pharmacology

Ресей, Kursk

A. Kornilov

Kursk State Medical University

Email: kornilovaa@kursksmu.net
ORCID iD: 0000-0002-0197-9826
SPIN-код: 5736-4098

Cand. Sci. (Med.), Associate Professor, Department of Clinical Pharmacology

Ресей, Kursk

O. Levashova

Kursk State Medical University

Email: levashovaov@kursksmu.net
ORCID iD: 0000-0002-4536-6263
SPIN-код: 3242-2235

Cand. Sci. (Med.), Associate Professor, Associate Professor at the Department of Clinical Pharmacology

Ресей, Kursk

Yu. Zhilyaeva

Kursk State Medical University

Хат алмасуға жауапты Автор.
Email: uliazhilyaeva85@yandex.ru
ORCID iD: 0000-0002-3844-6062
SPIN-код: 9825-0932

Cand. Sci. (Med.), Associate Professor, Department of Internal Medicine No. 2

Ресей, Kursk

N. Bachinsky

Nicolae Testemitanu State University of Medicine and Pharmacy

Email: nicolae.bacinschi@usmf.md
ORCID iD: 0000-0003-4854-5715

Dr. Sci. (Med.), Head of Department of Pharmacology and Clinical Pharmacology

Молдавия, Chisinau

L. Podgurski

Nicolae Testemitanu State University of Medicine and Pharmacy

Email: nicolae.bacinschi@usmf.md
ORCID iD: 0000-0002-5922-7838

Cand. Sci. (Med.), Associate Professor, Department of Pharmacology and Clinical Pharmacology

Молдавия, Chisinau

L. Tsurkan

Nicolae Testemitanu State University of Medicine and Pharmacy

Email: nicolae.bacinschi@usmf.md
ORCID iD: 0000-0003-1904-9464

Cand. Sci. (Med.), Associate Professor, Department of Pharmacology and Clinical Pharmacology

Молдавия, Chisinau

I. Golovach

Kursk State Medical University

Email: uliazhilyaeva85@yandex.ru
ORCID iD: 0009-0004-6345-0823
SPIN-код: 4550-2186

Department of Clinical Pharmacology

Ресей, Kursk

Әдебиет тізімі

  1. Яковец Е.А., Масленникова А.П. Оценка эффективности профилактики рецидивирующей инфекции нижних мочевыводящих путей, вызванной Escherichia сoli, у женщин. Фармакология & Фармакотерапия. 2022;3:18–23. [Yakovets E.A., Maslennikova A.P. Evaluation of the effectiveness of prevention of recurrent lower urinary tract infection caused by Escherichia coli in women. Farmakologiya Farmakoterapia. 2022;3:18–23 (In Russ.)]. https://dx.doi.org/10.46393/27132129_2022_3_18
  2. Никифоровский Н.К., Степанькова Е.А., Сухорукова А.О. Инфекции мочевыводящих путей у беременных (обзор). Сибирский научный медицинский журнал. 2020;40(5):18–23. [Nikiforovskii N.K., Stepan’kova E.A., Sukhorukova A.O. Urinary tract infections in pregnant women (review). Sibirskii nauchnyi meditsinskii zhurnal. 2020;40(5):18–23. (In Russ.)]. https://dx.doi.org/10.15372/SSMJ20200502
  3. Girma A., Aemiro A., Workineh D., Tamir D. Magnitude, Associated Risk Factors, and Trend Comparisons of Urinary Tract Infection among Pregnant Women and Diabetic Patients: A Systematic Review and Meta-Analysis. J Pregnancy. 2023;2023:8365867. https://dx.doi.org/10.1155/2023/8365867
  4. Гайбуллаев А.А., Абдуризаев А.А., Гайбуллаев О.А. Распространенность и факторы риска развития инфекции мочевыводящих путей у женщин репродуктивного возраста. Урология. 2020;3:46–9. [Gaibullaev A.A., Abdurizaev A.A., Gaibullaev O.A. Prevalence and risk factors for urinary tract infection in women of reproductive age. Urologiya. 2020;3:46–9. (In Russ.)]. https://dx.doi.org/10.18565/urology.2020.3.46-49
  5. Малаева Е.Г. Инфекции мочевыводящих путей и микробиота. Проблемы здоровья и экологии. 2021;18(3):5–14. [Malaeva E.G. Urinary tract infections and microbiota. Probl Zdor Ehkol. 2021;18(3):5–14. (In Russ.)]. https://dx.doi.org/10.51523/2708-6011.2021-18-3-1
  6. Гамидов С.И., Шатылко Т.В., Гасанов Н.Г. Терапия инфекции мочевыводящих путей на фоне уратного нефролитиаза. Русский медицинский журнал. 2019;27(2):48–52. [Gamidov S.I., Shatylko T.V., Gasanov N.G. Treatment of urinary tract infection in the context of urate nephrolithiasis. Russkiy meditsinskiy zhurnal=Russian Medical Journal. 2019;27(2):48–52. (In Russ.)].
  7. Смольянинова Д.С., Батищева Г.А., Батищев С.А. Антибиотикорезистентность при лечении инфекции мочевыводящих путей у пациентов с мочекаменной болезнью. Кардиоваскулярная терапия и профилактика. 2022;21(Suppl. 2):93. [Smol’yaninova D.S., Batishcheva G.A., Batishchev S.A. Antibiotic resistance in the treatment of urinary tract infection in patients with urolithiasis. Kardiovask Ter Profilakt. 2022;21(Suppl. 2):93. (In Russ.)].
  8. Зайцев А.В., Ширяев А.А., Ким Ю.А. и др. Инфекции мочевыводящих путей. Современная тактика врача-уролога. Русский медицинский журнал. 2019;27(11):21–6. [Zaitsev A.V., Shiryaev A.A., Kim Yu.A., et al. Urinary tract infections. Modern tactics of a urologist. Russkiy meditsinskiy zhurnal=Russian Medical Journal. 2019;27(11):21–6. (In Russ.)].
  9. Мельников В.Л., Митрофанова Н.Н., Синявина К.М., Шутихин В.О. Актуальные вопросы антибактериальной терапии инфекций мочевыводящих путей (обзор литературы). Справочник врача общей практики. 2019;8:63–72. [Mel’nikov V.L., Mitrofanova N.N., Sinyavina K.M., Shutikhin V.O. Current issues in antibacterial therapy of urinary tract infections (literature review).Spravochnik Vracha Obshchei Praktiki. 2019;8:63–72. (In Russ.)].
  10. Pietropaolo A. Urinary Tract Infections: Prevention, Diagnosis, and Treatment. J Clin Med. 2023;12(15):5058. https://dx.doi.org/10.3390/jcm12155058
  11. Lambert H., Shen X., Chai J., et al. Prevalence, drivers and surveillance of antibiotic resistance and antibiotic use in rural China: Interdisciplinary study. PLOS Glob Public Health. 2023;3(8):e0001232. https://dx.doi.org/10.1371/journal.pgph.0001232
  12. Lala V., Leslie S.W., Minter D.A. Acute Cystitis. StatPearls. Treasure Island (FL), 2023. URL: https://www.ncbi.nlm.nih.gov/books/NBK430685
  13. Пронина И.С. Антибактериальная терапия обострения хронического пиелонефрита в условиях реальной клинической практики. Бюллетень медицинских интернет-конференций. 2014;4(5):794. [Pronina I.S. Antibacterial therapy of exacerbation of chronic pyelonephritis in real clinical practice. Byull Med Internet-konferent. 2014;4(5):794 (In Russ.)].
  14. Деревянко Т.И., Придчин С.В., Рыжкова Э.В. Комплексная терапия и профилактика обострений калькулезного пиелонефрита. Урология. 2023;2:111–4. [Derevyanko T.I., Pridchin S.V., Ryzhkova Eh.V. Complex therapy and prevention of exacerbations of calculous pyelonephritis. Urologiya. 2023;2:111–4 (In Russ.)]. https://dx.doi.org/10.18565/urology.2023.2.111-114
  15. Amin A., Noureen R., Iftikhar A., et al. Uropathogenic bacteria and deductive genomics towards antimicrobial resistance, virulence, and potential drug targets. Int Microbiol. 2024;27(1):325–35. https://dx.doi.org/10.1007/s10123-023-00416-3
  16. Поветкин С.В., Гикавый В.И., Левашова О.В. и др. Сравнительная фармакоэпидемиологическая характеристика назначений антибактериальных препаратов, применяемых у больных с инфекцией нижних дыхательных путей в условиях типичной практики г. Курска и г. Кишинева. Человек и его здоровье. 2022;25(4):44–53. [Povetkin S.V., Gikavyi V.I., Levashova O.V., et al. Comparative pharmacoepidemiological characteristics of prescriptions of antibacterial drugs used in patients with lower respiratory tract infection in typical practice conditions of Kursk and Chisinau. Chelovek i ego zdorov’e. 2022;25(4):44–53. (In Russ.)]. https://dx.doi.org/10.21626/vestnik/2022-04/05
  17. Lelie-van der Zande R., Bouvy M., Teichert M. Adherence to guideline recommendations for urinary tract infections in adult women: a cross-sectional study. Prim Health Care Res Dev. 2021;22:e11. https://dx.doi.org/10.1017/S1463423621000116
  18. van der Zande R.L., Koster E.S., Teichert M., Bouvy M.L. Survey on general practitioners’ and pharmacists’ opinions regarding patient-initiated treatment of recurring urinary tract infections. Int J Clin Pharm. 2021;43(6):1630–7. https://dx.doi.org/10.1007/s11096-021-01295-2
  19. Blix H.S., Bergman J., Schjøtt J. How are antibacterials used in nursing homes? Results from a point-prevalence prescription study in 44 Norwegian nursing homes. Pharmacoepidemiol Drug Saf. 2010;19(10):1025–30. https://dx.doi.org/10.1002/pds.1980
  20. Рафальский В.В., Моисеева Е.М. Эпидемиология неосложненных внебольничных инфекций мочевыводящих путей в Российской Федерации. Вестник урологии. 2018;6(2):30–7. [Rafal’skii V.V., Moiseeva E.MEpidemiology of uncomplicated community-acquired urinary tract infections in the Russian Federation. Vestnik Urologii. 2018;6(2):30–7 (In Russ.)]. https://dx.doi.org/10.21886/2308-6424-2018-6-2-30-37
  21. Khatoon I., Khanam S., Azam A., et al. Incidence Pattern, Antibiotic Susceptibility Pattern and Associated Risk Factors of Bacterial Uropathogens Among General Population of Pakistan. Infect Drug Resist. 2023;16:4995–5005. https://dx.doi.org/10.2147/IDR.S418045
  22. Ku J.H, Bruxvoort K.J, Salas S.B, et al. Multidrug Resistance of Escherichia coli From Outpatient Uncomplicated Urinary Tract Infections in a Large United States Integrated Healthcare Organization. Open Forum Infect Dis. 2023;10(7):ofad287. https://dx.doi.org/10.1093/ofid/ofad287
  23. Боровиков В.П., Боровиков И.П. Statistica: Статистический анализ и обработка данных в среде Windows. М., 1998. 608 c. [Borovikov V.P., Borovikov I.P. Statistica: Statistical analysis and data processing in the Windows environment. M., 1998. 608 р. (In Russ.)].
  24. Гланц С. Медико-биологическая статистика. М., 1999. 459 с. [Glants S. Medical and biological statistics. M., 1999. 459 р. (In Russ.)].
  25. EAU Guidelines on Urological Infections 2023: European Association of Urology URL: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Urological-infections-2023.pdf (accessed: 24.12.2023).
  26. Клинические рекомендации: Хронический пиелонефрит у взрослых. 2019. Министерство здравоохранения Российской Федерации: [сайт]. URL: http://disuria.ru/_ld/9/998_kr16N11N20p9mz.pdf (дата обращения: 24.12.2023). [Clinical guidelines: Chronic pyelonephritis in adults. 2019. Ministry of Health of the Russian Federation: [website].URL: http://disuria.ru/_ld/9/998_kr16N11N20p9mz.pdf (accessed 24.12.2023) (In Russ.)].
  27. Сигитова О.Н. Болезни почек и мочевыводящих путей. Инфекции мочевых путей: методические рекомендации для терапевтов. М., 2022. 20 с. [Sigitova O.N. Diseases of the kidneys and urinary tract. Urinary tract infections: guidelines for therapists. M., 2022. 20 р. (In Russ.)].
  28. Хронический пиелонефрит и хроническая болезнь почек в практике врача поликлиники. Под ред. В.Н. Лариной. М., 2023. 144 с. [Chronic pyelonephritis and chronic kidney disease in the practice of a polyclinic physician. Ed. by V.N. Larina. M., 2023. 144 р. (In Russ.)]. https://dx.doi.org/10.33029/9704-7717-5-CPN-2023-1-144
  29. Луцет И.А., Новиков Д.Е., Решетько О.В. Особенности антибактериальной терапии обострения хронического пиелонефрита: фармакоэпидемиологическое исследование. Фармакоэкономика: теория и практика. 2017;5(1):88. [Lutset I.A., Novikov D.E., Reshet’ko O.V. Features of antibacterial therapy for exacerbation of chronic pyelonephritis: a pharmacoepidemiological study. Farmakoehkonomika: Teoriya i Praktika. 2017;5(1):88 (In Russ.)]. https://dx.doi.org/10.30809/phe.1.2017.17
  30. Lin K., Zahlanie Y., Ortwine J.K., et al. A retrospective review of oral cephalosporins versus fluoroquinolones for the treatment of pyelonephritis. PLoS One. 2022;17(9):e0274194. https://dx.doi.org/10.1371/journal.pone.0274194
  31. Fosse P.E, Brinkman K.M., Brink H.M., et al. Comparing outcomes among outpatients treated for pyelonephritis with oral cephalosporins versus first-line agents. Int J Antimicrob Agents. 2022;59(4):106560. https://dx.doi.org/10.1016/j.ijantimicag.2022.106560
  32. Мамчик Н.П., Батищева Г.А., Габбасова Н.В. и др. Структура и резистентность ведущих уропатогенов внебольничных инфекций мочевых путей в г. Воронеже за период 2013–2014 гг. Медицинский альманах. 2017;4(49):63–5. [Mamchik N.P., Batishcheva G.A., Gabbasova N.V., et al. Structure and resistance of leading uropathogens of community-acquired urinary tract infections in Voronezh for the period 2013–2014. Med Al’manakh. 2017;4(49):63–5. (In Russ.)].
  33. Зайцев А.В. Особенности лечения и профилактики неосложненной инфекции нижних мочевыводящих путей у женщин. Эффективная фармакотерапия. 2015;4:22–32. [Zaitsev A.V. Features of treatment and prevention of uncomplicated lower urinary tract infection in women. Ehffektivnaya Farmakoterapiya. 2015;4:22–32. (In Russ.)].
  34. Абрамович А.А., Стяжкина С.Н., Соколов А.В. и др. Актуальные проблемы пиелонефрита в современных условиях. Медико-фармацевтический журнал «Пульс». 2019;21(8):42–6. [Abramovich A.A., Styazhkina S.N., Sokolov A.V., et al. Actual problems of pyelonephritis in modern conditions. Med-farmatsevtich J «Pul’S». 2019;21(8):42–6. (In Russ.)]. https://dx.doi.org/10.26787/nydha-2686-6846-2019-21-8-42-46
  35. Дубский С.А., Бурчаков Д.И. Диагностика и лечение неосложненных инфекций мочевых путей в свете клинических рекомендаций 2022 года. Женская клиника. 2023;1:41–51. [Dubskii S.A., Burchakov D.I. Diagnosis and treatment of uncomplicated urinary tract infections in light of clinical guidelines for 2022. Zhenskaya Klinika. 2023;1:41–51. (In Russ.)].
  36. Bader M.S., Loeb M., Leto D., Brooks A.A. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgrad Med. 2020;132(3):234–50. https://dx.doi.org/10.1080/00325481.2019.1680052
  37. Ballash G.A., Diaz-Campos D., van Balen J.C., et al. Previous Antibiotic Exposure Reshapes the Population Structure of Infecting Uropathogenic Escherichia coli Strains by Selecting for Antibiotic Resistance over Urovirulence. Microbiol Spectr. 2023;11(4):e0524222. https://dx.doi.org/10.1128/spectrum.05242-22
  38. Rovelsky S.A, Vu M., Barrett A.K, et al. Cunningham F., Madaras-Kelly K. J.; UTI Management Improvement Group. Outpatient treatment and clinical outcomes of bacteriuria in veterans: A retrospective cohort analysis. Antimicrob Steward Healthc Epidemiol. 2022;2(1):e168. https://dx.doi.org/10.1017/ash.2022.285

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2025